Zhejiang Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Senile Chronic Diseases, Department of Geriatrics, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, People's Republic of China.
Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.
Drug Des Devel Ther. 2024 Sep 18;18:4183-4202. doi: 10.2147/DDDT.S479881. eCollection 2024.
Currently, ischemic stroke (IS) continues to significantly contribute to functional deterioration and reduced life quality. Regrettably, the choice of neuro-rehabilitation interventions to enhance post-IS outcomes is limited. Guanxinning tablet (GXNT), a multi-component medicine composed of Danshen and Chuanxiong, has demonstrated neuroprotective potential against ischemic brain injury and diabetic encephalopathy. However, the therapeutic impact of GXNT on post-IS functional outcomes and pathological injury, as well as the underlying molecular mechanisms and anti-IS active substances, remain unclear.
To answer the above questions, neurological and behavioral assessment, cerebral lesions, and blood-brain barrier (BBB) integrity were combined to comprehensively investigate GXNT's pharmacodynamic effects against post-IS injury. The possible molecular mechanisms were revealed through transcriptome sequencing coupled with experimental verification. Furthermore, the brain tissue distribution of main components in GXNT, behavioral changes of IS zebrafish, and molecular docking were integrated to identify the anti-IS active compounds.
Treatment with GXNT significantly mitigated the functional deficits, cerebral cortex lesions, and BBB disruption following IS. Transcriptome sequencing and bioinformatics analysis suggested that complement and coagulation cascades as well as inflammation might play crucial roles in the GXNT's therapeutic effects. Molecular biology experiments indicated that GXNT administration effectively normalized the abnormal expression of mRNA and protein levels of key targets related to complement and coagulation cascades (eg C3 and F7) and inflammation (eg MMP3 and MMP9) in the impaired cortical samples of IS mice. The locomotor promotion in IS zebrafish as well as favorable affinity with key proteins (C3, F7, and MMP9) highlighted anti-IS activities of brain-permeating constituents (senkyunolide I and protocatechuic acid) of GXNT.
Taken together, these intriguing findings indicate that GXNT intervention exerts a beneficial effect against post-IS injury via regulating the complement and coagulation cascades pathway and mobilizing inflammatory network. Senkyunolide I and protocatechuic acid show promise as anti-IS active compounds.
目前,缺血性脑卒中(IS)仍然导致功能恶化和生活质量下降。遗憾的是,用于增强 IS 后结果的神经康复干预措施的选择有限。冠心宁片(GXNT)是一种由丹参和川芎组成的多成分药物,已被证明对缺血性脑损伤和糖尿病性脑病具有神经保护作用。然而,GXNT 对 IS 后功能结果和病理损伤的治疗影响,以及潜在的分子机制和抗 IS 活性物质,尚不清楚。
为了回答上述问题,将神经学和行为评估、脑损伤和血脑屏障(BBB)完整性相结合,全面研究 GXNT 对 IS 后损伤的药效作用。通过转录组测序结合实验验证揭示了可能的分子机制。此外,整合 GXNT 主要成分在脑组织中的分布、IS 斑马鱼的行为变化和分子对接,以鉴定抗 IS 活性化合物。
GXNT 治疗可显著减轻 IS 后的功能缺陷、大脑皮层损伤和 BBB 破坏。转录组测序和生物信息学分析表明,补体和凝血级联以及炎症可能在 GXNT 的治疗作用中发挥关键作用。分子生物学实验表明,GXNT 给药可有效调节 IS 小鼠受损皮质样本中补体和凝血级联(如 C3 和 F7)和炎症(如 MMP3 和 MMP9)相关关键靶标 mRNA 和蛋白水平的异常表达。IS 斑马鱼的运动促进以及与关键蛋白(C3、F7 和 MMP9)的良好亲和力突出了 GXNT 的脑穿透成分(色烯内酯 I 和原儿茶酸)的抗 IS 活性。
综上所述,这些有趣的发现表明,GXNT 干预通过调节补体和凝血级联途径和动员炎症网络,对 IS 后损伤发挥有益作用。色烯内酯 I 和原儿茶酸有望成为抗 IS 活性化合物。